The therapeutic potential of BRD4 in cardiovascular disease

No abstract is available for this paper.

• Publication year

  2020

• Venue

  Hypertension Research

• Publication date

  2020-05-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/s41440-020-0459-4PMID 32409773
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Thyrotropin aggravates atherosclerosis by promoting macrophage inflammation in plaques

  2019cited by this paper
• BRD4 inhibitor and histone deacetylase inhibitor synergistically inhibit the proliferation of gallbladder cancer in vitro and in vivo

  2019cited by this paper
• Multicenter Preclinical Validation of BET Inhibition for the Treatment of Pulmonary Arterial Hypertension.

  2019cited by this paper
• Inhibition of Brd4 alleviates renal ischemia/reperfusion injury-induced apoptosis and endoplasmic reticulum stress by blocking FoxO4-mediated oxidative stress

  2019cited by this paper
• Apabetalone downregulates factors and pathways associated with vascular calcification.

  2019cited by this paper
• Inhibition of BRD4 attenuates transverse aortic constriction- and TGF-β-induced endothelial-mesenchymal transition and cardiac fibrosis.

  2019influential reference
• LncRNA HOXA-AS2 represses endothelium inflammation by regulating the activity of NF-κB signaling.

  2019cited by this paper
• Immunity and Inflammation in Atherosclerosis

  2019cited by this paper
• BRD4 Inhibitor AZD5153 Suppresses the Proliferation of Colorectal Cancer Cells and Sensitizes the Anticancer Effect of PARP Inhibitor

  2019cited by this paper
• Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism

  2019cited by this paper
• Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities

  2019cited by this paper
• BRD4 and Cancer: going beyond transcriptional regulation

  2018cited by this paper
• FOXM1 promotes pulmonary artery smooth muscle cell expansion in pulmonary arterial hypertension

  2018cited by this paper
• Inhibition of BRD4 attenuates cardiomyocyte apoptosis via NF‐&kgr;B pathway in a rat model of myocardial infarction

  2018cited by this paper
• Role of smooth muscle cells in vascular calcification: implications in atherosclerosis and arterial stiffness

  2018cited by this paper
• BRD4 expression in patients with essential hypertension and its effect on blood pressure in spontaneously hypertensive rats.

  2018cited by this paper
• Transcriptional addiction in cancer cells is mediated by YAP/TAZ through BRD4

  2018cited by this paper
• Implication of Inflammation and Epigenetic Readers in Coronary Artery Remodeling in Patients With Pulmonary Arterial Hypertension

  2017cited by this paper
• VEGF amplifies transcription through ETS1 acetylation to enable angiogenesis

  2017cited by this paper
• Hypoxia inducible factor as a therapeutic target for atherosclerosis.

  2017cited by this paper
• The suppression of bromodomain and extra‐terminal domain inhibits vascular inflammation by blocking NF‐κB and MAPK activation

  2017cited by this paper
• The lncRNA-HOXA-AS2/EZH2/LSD1 oncogene complex promotes cell proliferation in pancreatic cancer.

  2017cited by this paper
• Inhibition of BET proteins and epigenetic signaling as a potential treatment for osteoporosis.

  2017cited by this paper
• Knockdown of HOXA-AS2 suppresses proliferation and induces apoptosis in colorectal cancer.

  2017cited by this paper
• BET bromodomain inhibition suppresses innate inflammatory and profibrotic transcriptional networks in heart failure

  2017cited by this paper
• Coordinate activities of BRD4 and CDK9 in the transcriptional elongation complex are required for TGFβ-induced Nox4 expression and myofibroblast transdifferentiation

  2017cited by this paper
• BET Bromodomain Suppression Inhibits VEGF-induced Angiogenesis and Vascular Permeability by Blocking VEGFR2-mediated Activation of PAK1 and eNOS

  2016cited by this paper
• Signal-Dependent Recruitment of BRD4 to Cardiomyocyte Super-Enhancers Is Suppressed by a MicroRNA.

  2016cited by this paper
• Brd4 inhibition attenuates unilateral ureteral obstruction-induced fibrosis by blocking TGF-β-mediated Nox4 expression

  2016cited by this paper
• Trends and Outcomes of Pulmonary Arterial Hypertension-Related Hospitalizations in the United States: Analysis of the Nationwide Inpatient Sample Database From 2001 Through 2012.

  2016cited by this paper
• Bromodomain and extra‐terminal protein mimic JQ1 decreases inflammation in human vascular endothelial cells: Implications for pulmonary arterial hypertension

  2016cited by this paper
• Epigenetics of Notch1 regulation in pulmonary microvascular rarefaction following extrauterine growth restriction

  2015cited by this paper
• BET protein Brd4 activates transcription in neurons and BET inhibitor Jq1 blocks memory in mice

  2015cited by this paper
• BET Bromodomain Blockade Mitigates Intimal Hyperplasia in Rat Carotid Arteries.

  2015cited by this paper
• Cytokines in atherosclerosis: Key players in all stages of disease and promising therapeutic targets

  2015cited by this paper
• Bromodomain-Containing Protein 4: The Epigenetic Origin of Pulmonary Arterial Hypertension.

  2015influential reference
• BET protein inhibition mitigates acute myocardial infarction damage in rats via the TLR4/TRAF6/NF-κB pathway.

  2015cited by this paper
• BET Bromodomain Blockade Mitigates Intimal Hyperplasia in Rat Carotid Arteries

  2015cited by this paper
• Bromodomain-Containing Protein 4Novelty and Significance

  2015cited by this paper
• The mechanisms behind the therapeutic activity of BET bromodomain inhibition.

  2014cited by this paper
• The bromodomain protein inhibitor I-BET151 suppresses expression of inflammatory genes and matrix degrading enzymes in rheumatoid arthritis synovial fibroblasts

  2014cited by this paper
• Elevation of HDL-C in response to statin treatment is involved in the regression of carotid atherosclerosis.

  2014cited by this paper
• Role for DNA Damage Signaling in Pulmonary Arterial Hypertension

  2014cited by this paper
• Role of Reactive Oxygen Species in Neonatal Pulmonary Vascular Disease

  2014cited by this paper
• A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice.

  2014cited by this paper
• NF-κB directs dynamic super enhancer formation in inflammation and atherogenesis.

  2014cited by this paper
• Extrauterine growth restriction on pulmonary vascular endothelial dysfunction in adult male rats: the role of epigenetic mechanisms

  2014cited by this paper
• Achievement rates of Japan Atherosclerosis Society Guidelines 2007 LDL-cholesterol goals with rosuvastatin or atorvastatin in patients who had not achieved their goal with atorvastatin.

  2014cited by this paper
• The Bromodomain Protein Brd4 Insulates Chromatin from DNA Damage Signaling

  2013cited by this paper
• RVX-208, an Inducer of ApoA-I in Humans, Is a BET Bromodomain Antagonist

  2013cited by this paper
• RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain

  2013cited by this paper
• BET bromodomains mediate transcriptional pause release in heart failure.

  2013cited by this paper
• Signaling effectors underlying pathologic growth and remodeling of the heart.

  2013cited by this paper
• BET acetyl-lysine binding proteins control pathological cardiac hypertrophy.

  2013cited by this paper
• Statins in the primary prevention of cardiovascular disease

  2013cited by this paper
• Molecular basis of cardiac endothelial-to-mesenchymal transition (EndMT): differential expression of microRNAs during EndMT.

  2012cited by this paper
• Systemic endothelial dysfunction in children with idiopathic pulmonary arterial hypertension correlates with disease severity.

  2012cited by this paper
• BET domain co-regulators in obesity, inflammation and cancer

  2012cited by this paper
• Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial.

  2011cited by this paper
• Transforming growth factor (TGF)-β signaling in cardiac remodeling.

  2011cited by this paper
• A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome.

  2010cited by this paper
• Selective inhibition of BET bromodomains

  2010cited by this paper
• Faculty Opinions recommendation of Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA.

  2009cited by this paper
• Cooperative binding of two acetylation marks on a histone tail by a single bromodomain

  2009cited by this paper
• Pyrin Critical to Macrophage IL-1β Response to Francisella Challenge1

  2009cited by this paper
• The role of circulating mesenchymal progenitor cells (fibrocytes) in the pathogenesis of pulmonary fibrosis

  2009cited by this paper
• Brd4 Coactivates Transcriptional Activation of NF-κB via Specific Binding to Acetylated RelA

  2008cited by this paper
• Cardiac plasticity.

  2008cited by this paper
• How mitochondria produce reactive oxygen species

  2008cited by this paper
• The Double Bromodomain-containing Chromatin Adaptor Brd4 and Transcriptional Regulation*

  2007cited by this paper
• The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted

  2007cited by this paper
• Inflammation and Salt Sensitivity in the Early State of Hypertension

  2007cited by this paper
• The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology.

  2007cited by this paper
• Insulin resistance, chronic inflammatory state and the link with systemic lupus erythematosus-related coronary disease.

  2006cited by this paper
• Inflammation, atherosclerosis, and coronary artery disease.

  2005cited by this paper
• Cellular origins of fibroblasts: possible implications for organ fibrosis in systemic sclerosis

  2004cited by this paper
• Oxidative Stress and Vascular Disease

  2004cited by this paper
• Oxidative stress in severe pulmonary hypertension.

  2004cited by this paper
• VEGF and the quest for tumour angiogenesis factors

  2002cited by this paper
• Bromodomain: an acetyl‐lysine binding domain

  2002cited by this paper

• Bromodomain-containing protein 4 in inflammatory diseases: molecular mechanisms and therapeutic potential.

  2026cites this paper
• Inhibition of BRD4 activates the AKT-SIRT3 signaling pathway to suppress apoptosis and attenuate hyperoxia-induced lung injury

  2025cites this paper
• BRD4/MAP2K7/PGF Signaling Axis Promotes Senescence and Extracellular Matrix Metabolism of Nucleus Pulposus Cells in Intervertebral Disk Degeneration

  2025cites this paper
• Recent advances and strategies in BET bromodomain inhibition for drug discovery.

  2025cites this paper
• Andrographolide inhibits microglia inflammation and M1-like macrophage polarization after traumatic brain injury by regulating BRD4 expression

  2025cites this paper
• Endothelial–Mesenchymal Transition and Possible Role of Cytokines in Streptozotocin-Induced Diabetic Heart

  2025cites this paper
• Advances in BRD proteins in cardiovascular pathophysiology and therapy: A review.

  2025cites this paper
• Apabetalone (RVX-208): A Potential Epigenetic Therapy for the Treatment of Cardiovascular, Renal, Neurological, Viral, and Cancer Disorders.

  2024cites this paper
• BRD4 as an emerging epigenetic therapeutic target for inflammatory bowel disease.

  2024cites this paper
• Vascular restenosis following paclitaxel-coated balloon therapy is attributable to NLRP3 activation and LIN9 upregulation

  2024cites this paper
• BRD4 absence inactivates endoplasmic reticulum stress to retard dehydroepiandrosterone-triggered ovarian granular cell apoptosis in polycystic ovary syndrome via GRP78.

  2024cites this paper
• Novel BRD4-p53 Inhibitor SDU-071 Suppresses Proliferation and Migration of MDA-MB-231 Triple-Negative Breast Cancer Cells.

  2024cites this paper
• Emerging roles of HOTAIR lncRNA in the pathogenesis and prognosis of cardiovascular diseases.

  2024cites this paper
• Phenotypic switching of vascular smooth muscle cells in atherosclerosis, hypertension, and aortic dissection

  2024influential citation
• BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications

  2023cites this paper
• Tensions in Taxonomies: Current Understanding and Future Directions in the Pathobiologic Basis and Treatment of Group 1 and Group 3 Pulmonary Hypertension.

  2023cites this paper
• Epigenetic Reader Bromodomain-Containing Protein 4 in Aging-Related Vascular Pathologies and Diseases: Molecular Basis, Functional Relevance, and Clinical Potential

  2023cites this paper
• Pyronaridine as a Bromodomain-Containing Protein 4-N-Terminal Bromodomain (BRD4-BD1) Inhibitor: In Silico Database Mining, Molecular Docking, and Molecular Dynamics Simulation

  2023cites this paper
• Integrated omics analysis of coronary artery calcifications and myocardial infarction: the Framingham Heart Study

  2023cites this paper
• Genetic variations in relation to bleeding and pharmacodynamics of dabigatran in Chinese patients with nonvalvular atrial fibrillation: A nationwide multicentre prospective cohort study

  2022cites this paper
• PLEK2 promotes the proliferation and migration of non-small cell lung cancer cells in a BRD4-dependent manner

  2022cites this paper
• Association of smoking type, status, number times of smoking and their effect on infected people by COVID-19

  2022cites this paper
• Silencing of Long Noncoding RNA TUG1 Ameliorates Atherosclerosis-Induced Myocardial Injury by Upregulating microRNA-30b-3p and Downregulating Brd4

  2022cites this paper
• Estrogen signaling as a bridge between the nucleus and mitochondria in cardiovascular diseases

  2022cites this paper
• Discovery of 2-((2-methylbenzyl)thio)-6-oxo-4-(3,4,5-trimethoxyphenyl)-1,6-dihydropyrimidine-5-carbonitrile as a novel and effective bromodomain and extra-terminal (BET) inhibitor for the treatment of sepsis.

  2022cites this paper
• Dual HDAC–BRD4 inhibitors endowed with antitumor and antihyperalgesic activity

  2022cites this paper
• Beyond the marks: reader-effectors as drivers of epigenetics and chromatin engineering.

  2022cites this paper
• Targeting Bromodomain-Selective Inhibitors of BET Proteins in Drug Discovery and Development.

  2022cites this paper
• Post-Translational Modifications of BRD4: Therapeutic Targets for Tumor

  2022cites this paper
• BRD4 Inhibition Suppresses Senescence and Apoptosis of Nucleus Pulposus Cells by Inducing Autophagy during Intervertebral Disc Degeneration: An In Vitro and In Vivo Study

  2022cites this paper
• Stem cell therapy for pulmonary arterial hypertension: An update.

  2022cites this paper
• Targeting Epigenetics and Non-coding RNAs in Myocardial Infarction: From Mechanisms to Therapeutics

  2021cites this paper
• A BRD’s (BiRD’s) eye view of BET and BRPF bromodomains in neurological diseases

  2021cites this paper
• Genome-wide CRISPR-Cas9 screens identify mechanisms of BET bromodomain inhibitor sensitivity

  2021cites this paper
• Histone Deacetylases (HDACs) and Atherosclerosis: A Mechanistic and Pharmacological Review

  2020cites this paper